# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-125216
Filing Date
2023-04-28
Accepted
2023-04-28 11:15:59
Documents
6
Period of Report
2023-06-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d464571ddef14a.htm | DEF 14A | 554391
2 | GRAPHIC | g464571g01a01.jpg | GRAPHIC | 78856
3 | GRAPHIC | g464571g02a02.jpg | GRAPHIC | 632077
4 | GRAPHIC | g464571g30h04.jpg | GRAPHIC | 23027
5 | GRAPHIC | g464571page061.jpg | GRAPHIC | 150411
6 | GRAPHIC | g464571page062.jpg | GRAPHIC | 108511
| Complete submission text file | 0001193125-23-125216.txt |  | 1907683

Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 033-80623 | Film No.: 23861784
SIC: 2835 In Vitro & In Vivo Diagnostic Substances